Sponsor Pipeline

XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd. Clinical Trial Pipeline

Data updated daily from ClinicalTrials.gov — last refresh 2026-08-16
6
Active Trials
4
Recruiting
2
Disease Areas
Active Trials by Phase
Phase 2
1
Phase 1/2
1
Phase 1
4
Active Trials
NCT IDTitleConditionStatus
Phase 2
NCT06974968 Efficacy of iPSC-Derived Motor Neuron Cells (XS228) in Subacute Spinal Cord Injury: A… Spinal Cord Injury Not Yet Recruiting
Phase 1/2
NCT07166757 Clinical Study to Evaluate XS411 in Treatment of Early-onset Parkinson's Disease Parkinson Disease (PD) Recruiting
Phase 1
NCT07080775 The Safety and Tolerability of XS411CN Injection in Treatment of Primary Parkinson's… Parkinson's Disease Recruiting
NCT07118319 The Safety, Tolerability and Preliminary Efficacy of Derived Motor Neuron Progenitor… Amyotrophic Lateral Sclerosis (ALS) Recruiting
NCT06976229 Safety and Early Efficacy of iPSC-Derived Motor Neuron Progenitor Cells (XS228) in… Spinal Cord Injury Recruiting
NCT07617012 The Safety, Tolerability, and Efficacy of Dopaminergic Neural Progenitor Cells (XS411CN… the Treatment of Multiple System Atrophy Parkinsonian Variant (MSA-P) Not Yet Recruiting
Disease Areas
Get alerts when XellSmart Bio-Pharmaceutical (Suzhou) Co., Ltd.'s trials change
Status changes, date slips, and new filings — detected daily, delivered to your inbox.
Start monitoring free